MedWatch

Orifarm ramps up growth plans following USD 703m acquisition

In a just few years, Orifarm has become one of Denmark’s biggest pharmaceutical firms. The company is now on a hunt for new acquisitions.

Erik Sandberg, CEO of Orifarm | Photo: PR /Orifarm

A historical acquisition for no less than DKK 4.6bn (USD 703m) was the beginning of a growth journey for Danish pharmaceutical firm Orifarm – but the adventure is far from over.

The purchase has catapulted Orifarm to the upper echelons of Danish pharmaceutical companies, and company CEO Erik Sandberg is now looking towards 2025.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs